Does the media refer more to XERS or AMRX?

In the previous week, Amneal Pharmaceuticals had 18 more articles in the media than Xeris Biopharma. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 3 mentions for Xeris Biopharma. Amneal Pharmaceuticals' average media sentiment score of 0.88 beat Xeris Biopharma's score of 0.77 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRRK or XERS?

In the previous week, Scholar Rock had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 8 mentions for Scholar Rock and 3 mentions for Xeris Biopharma. Scholar Rock's average media sentiment score of 0.98 beat Xeris Biopharma's score of 0.77 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or XERS?

In the previous week, Dianthus Therapeutics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 3 mentions for Xeris Biopharma. Dianthus Therapeutics' average media sentiment score of 1.39 beat Xeris Biopharma's score of 0.77 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TWST or XERS?

In the previous week, Twist Bioscience had 11 more articles in the media than Xeris Biopharma. MarketBeat recorded 14 mentions for Twist Bioscience and 3 mentions for Xeris Biopharma. Twist Bioscience's average media sentiment score of 1.24 beat Xeris Biopharma's score of 0.77 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XERS or ORKA?

In the previous week, Oruka Therapeutics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Oruka Therapeutics and 3 mentions for Xeris Biopharma. Oruka Therapeutics' average media sentiment score of 1.25 beat Xeris Biopharma's score of 0.77 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xeris Biopharma (XERS) Competitors

$8.13 +0.05 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$8.10 -0.03 (-0.36%)

As of 04:20 PM Eastern

Compare

XERS vs. AMRX, SRRK, DNTH, TWST, and ORKA

Should you buy Xeris Biopharma stock or one of its competitors? MarketBeat compares Xeris Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xeris Biopharma include Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), Dianthus Therapeutics (DNTH), Twist Bioscience (TWST), and Oruka Therapeutics (ORKA).

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Amneal Pharmaceuticals had 18 more articles in the media than Xeris Biopharma. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 3 mentions for Xeris Biopharma. Amneal Pharmaceuticals' average media sentiment score of 0.88 beat Xeris Biopharma's score of 0.77 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	4.46	$550K	$0.06	135.50
Amneal Pharmaceuticals	$3.02B	1.99	$72.06M	$0.49	38.47

Amneal Pharmaceuticals has a net margin of 5.05% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Xeris Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 32.84%. Amneal Pharmaceuticals has a consensus target price of $17.67, indicating a potential downside of 6.28%. Given Xeris Biopharma's higher possible upside, research analysts plainly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 11 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Scholar Rock presently has a consensus price target of $56.21, suggesting a potential upside of 22.60%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 32.84%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Scholar Rock had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 8 mentions for Scholar Rock and 3 mentions for Xeris Biopharma. Scholar Rock's average media sentiment score of 0.98 beat Xeris Biopharma's score of 0.77 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of 3.81% compared to Scholar Rock's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Xeris Biopharma	3.81%	735.00%	3.24%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Xeris Biopharma	$314.85M	4.46	$550K	$0.06	135.50

Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Summary

Scholar Rock and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Dianthus Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Dianthus Therapeutics presently has a consensus price target of $117.82, suggesting a potential upside of 11.13%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 32.84%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Dianthus Therapeutics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 3 mentions for Xeris Biopharma. Dianthus Therapeutics' average media sentiment score of 1.39 beat Xeris Biopharma's score of 0.77 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,338.09	-$162.34M	-$4.13	N/A
Xeris Biopharma	$314.85M	4.46	$550K	$0.06	135.50

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Xeris Biopharma has a net margin of 3.81% compared to Dianthus Therapeutics' net margin of -12,998.50%. Xeris Biopharma's return on equity of 735.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Xeris Biopharma	3.81%	735.00%	3.24%

Summary

Xeris Biopharma beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Xeris Biopharma (NASDAQ:XERS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Xeris Biopharma has a net margin of 3.81% compared to Twist Bioscience's net margin of -19.85%. Xeris Biopharma's return on equity of 735.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Xeris Biopharma	3.81%	735.00%	3.24%

Twist Bioscience presently has a consensus target price of $90.30, indicating a potential downside of 10.65%. Xeris Biopharma has a consensus target price of $10.80, indicating a potential upside of 32.84%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

42.8% of Xeris Biopharma shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xeris Biopharma has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$409.48M	15.37	-$77.67M	-$1.33	N/A
Xeris Biopharma	$314.85M	4.46	$550K	$0.06	135.50

In the previous week, Twist Bioscience had 11 more articles in the media than Xeris Biopharma. MarketBeat recorded 14 mentions for Twist Bioscience and 3 mentions for Xeris Biopharma. Twist Bioscience's average media sentiment score of 1.24 beat Xeris Biopharma's score of 0.77 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Summary

Xeris Biopharma beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Oruka Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Oruka Therapeutics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Oruka Therapeutics and 3 mentions for Xeris Biopharma. Oruka Therapeutics' average media sentiment score of 1.25 beat Xeris Biopharma's score of 0.77 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$314.85M	4.46	$550K	$0.06	135.50
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Xeris Biopharma has a net margin of 3.81% compared to Oruka Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Xeris Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 32.84%. Oruka Therapeutics has a consensus target price of $134.30, suggesting a potential upside of 41.68%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Xeris Biopharma beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.40B	$11.48B	$6.81B	$12.68B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	135.50	793.98	281.02	25.13
Price / Sales	4.46	747.05	575.02	81.09
Price / Cash	80.67	14.82	28.64	34.82
Price / Book	101.63	10.39	11.02	6.21
Net Income	$550K	$2.80B	$3.48B	$347.49M
7 Day Performance	-0.97%	0.31%	0.57%	0.89%
1 Month Performance	-1.81%	-3.69%	-4.14%	-3.60%
1 Year Performance	51.12%	156.59%	63.23%	20.46%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.8043 of 5 stars	$8.13 +0.6%	$10.80 +32.8%	+50.2%	$1.40B	$314.85M	135.50	290	News Coverage Positive News Upcoming Earnings
AMRX Amneal Pharmaceuticals	2.9014 of 5 stars	$18.09 +0.9%	$16.60 -8.2%	+134.0%	$5.72B	$3.02B	47.61	8,500	Analyst Forecast
SRRK Scholar Rock	3.3716 of 5 stars	$48.93 +2.6%	$56.00 +14.4%	+30.1%	$5.71B	N/A	N/A	140	Upcoming Earnings
DNTH Dianthus Therapeutics	2.3246 of 5 stars	$104.49 +0.6%	$117.82 +12.8%	+419.3%	$5.68B	$2.04M	N/A	80	Positive News Upcoming Earnings
TWST Twist Bioscience	1.5441 of 5 stars	$86.54 -4.1%	$90.30 +4.3%	+171.8%	$5.62B	$409.48M	N/A	990	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. AMRX, SRRK, DNTH, TWST, and ORKA

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

How does Xeris Biopharma compare to Scholar Rock?

Summary

How does Xeris Biopharma compare to Dianthus Therapeutics?

Summary

How does Xeris Biopharma compare to Twist Bioscience?

Summary

How does Xeris Biopharma compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. AMRX, SRRK, DNTH, TWST, and ORKA

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Does the media refer more to XERS or AMRX?

Which has higher valuation & earnings, XERS or AMRX?

Is XERS or AMRX more profitable?

Which has more risk & volatility, XERS or AMRX?

Do analysts rate XERS or AMRX?

Do insiders and institutionals believe in XERS or AMRX?

Summary

How does Xeris Biopharma compare to Scholar Rock?

Do analysts prefer SRRK or XERS?

Does the media favor SRRK or XERS?

Is SRRK or XERS more profitable?

Do institutionals & insiders hold more shares of SRRK or XERS?

Which has preferable earnings and valuation, SRRK or XERS?

Which has more volatility and risk, SRRK or XERS?

Summary

How does Xeris Biopharma compare to Dianthus Therapeutics?

Which has more risk & volatility, DNTH or XERS?

Do analysts rate DNTH or XERS?

Does the media prefer DNTH or XERS?

Which has stronger valuation & earnings, DNTH or XERS?

Do insiders & institutionals have more ownership in DNTH or XERS?

Is DNTH or XERS more profitable?

Summary

How does Xeris Biopharma compare to Twist Bioscience?

Is TWST or XERS more profitable?

Do analysts rate TWST or XERS?

Do insiders & institutionals believe in TWST or XERS?

Which has preferable valuation & earnings, TWST or XERS?

Does the media prefer TWST or XERS?

Which has more volatility and risk, TWST or XERS?

Summary

How does Xeris Biopharma compare to Oruka Therapeutics?

Does the media refer more to XERS or ORKA?

Which has preferable valuation & earnings, XERS or ORKA?

Is XERS or ORKA more profitable?

Which has more risk & volatility, XERS or ORKA?

Do institutionals & insiders hold more shares of XERS or ORKA?

Do analysts prefer XERS or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools